Anemia, Endometrial Diseases
Conditions
Keywords
Erythropoietin, Endometrium, Doppler Ultrasonography
Brief summary
The purpose of this study to assess the proliferative effects of erythropoetin on human endometrium tissue by measuring the endometrial thickness, uterine artery and subendometrial blood flow in postmenopausal women.
Detailed description
20 postmenopausal women who are planned to treat with erythropoietin alpha for their renal conditions will be included to the study. Sample size was calculated with proper power analysis with accepting the difference of 1 mm in endometrial thickness as a significant change. After the informed consent, endometrial thickness (mm), uterine artery and subendometrial blood flow by doppler ultrasonography (RI, S/D) will be measured. Same measurements will be repeated on the 3rd day and 30th day. Patients' age, BMI, co-morbidities, administered erythropoietin doses will be noted. No adverse effect is expected with regard to the ultrasonographic examination. Date of the patients who do not attend for the appointments for repetitive examinations and uninterpretable doppler variables due to the atrophic uterus will be noted as the missing data and will be excluded from the study. Proper statistical analysis will be done.
Interventions
DRUGErythropoietin
Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Sponsors
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Fatih Sultan Mehmet Training and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Clinically condition with need for erythropoietin treatment such as anemia due to the renal failure or the need for hemodialysis. * Must be in postmenopausal period
Exclusion criteria
* Patients with any type of malignancy * Existence of any intracavitary mass which may affect endometrial thickness or blood flow such as endometrial polyps, myomas, intracavitary fluid etc. * Intrauterine device * Being on Hormon replacement therapy * Hysterectomized patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Endometrial Thickness Confirmed by Transvaginal Ultrasonography at 3th and 30th Days | within the first 3 and 30 days (plus or minus 3 days) after the erythropoietin treatment | Change from Baseline Endometrial Thickness Confirmed by Transvaginal |
Countries
Turkey (Türkiye)
Outcome results
None listed